Search

Your search keyword '"Uguen, Thomas"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Uguen, Thomas" Remove constraint Author: "Uguen, Thomas"
34 results on '"Uguen, Thomas"'

Search Results

2. Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study

3. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

5. THU-466 Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort

6. SAT-043 Liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma following neoadjuvant treatment with chemotherapy and radioembolization

7. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

10. Evaluation of a delayed liver transplant strategy for patients listed for hepatocellular carcinoma treated with resection or thermo-ablation as a bridge to liver transplantation; the DELTAS-HCC study

11. Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

12. Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort

13. Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.

15. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

18. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma

19. Unresectable HCC patients disposal in the new era of immunotherapy from the elitor study based on the french chief cohort

20. THU-498 - Evaluation of a delayed liver transplant strategy for patients listed for hepatocellular carcinoma treated with resection or thermo-ablation as a bridge to liver transplantation; the DELTAS-HCC study

21. OS-081 - Epidemiology and characteristics of hepatocellular carcinoma in France: results of the first 2000 patients in real-life situations from the French prospective chief cohort

22. OS-083-YI - Natural history and management of recurrent hepatocellular carcinoma after liver transplantation: a multicenter nationwide study

23. Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role

24. Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation

25. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and Y-loaded glass microsphere selective internal radiation therapy

26. FRI-363-Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation

27. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

28. Impact of HCV treatment on long term mortality in patients >= 70 years at the time of HCV infection diagnosis

29. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy.

30. Guide pratique de suivi du transplanté hépatique.

32. Recommandations pour le traitement de la constipation : une aide efficace de plus à la décision thérapeutique ! (1ère partie).

34. Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.

Catalog

Books, media, physical & digital resources